Business
Adial Pharmaceuticals and iRemedy Partner to Sell COVID-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales
CHARLOTTESVILLE, VA / ACCESSWIRE / September 22, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused
About this update from Adial Pharmaceuticals, Inc
[{"type":"text","content":"CHARLOTTESVILLE, VA / ACCESSWIRE / September 22, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and The iRemedy Healthcare Companies, Inc. (\"iRemedy\"), pioneers of the iRemedy medical supply marketplace platform, today announced that the two companies have commenced sales of FaStep COVID-19 IgG/IgM rapid antibody test kits to healthcare providers and hospitals through the iRemedy network and ecommerce platform.As reported previously, Adial has secured rights to distribute COVID-19 antibody tests to designated channel partners and customers. Antibody test kits distributed by Adial are FDA emergency use authorization (EUA) registered, 10-minute, ‘instant' point-of-care test devices for the qualitative detection of lgG and lgM antibodies specific to SARS-CoV-2 virus in human whole blood, serum or plasma specimens. During testing, the specimen reacts with antigen coated particles in the test cassette after droplets of blood from the subject are placed on the cassette's coated membrane.Tony Paquin, Co-Founder and Chief Executive Officer of iRemedy, commented, \"We are delighted to partner with Adial to advance sales of the FaStep COVID-19 antibody test kits across our network of U.S. healthcare providers and hospitals in order to help address the unmet market need for these differentiated test kits, given the prolonged and devastating impact of COVID-19. We see a significant market potential in these instant and efficient tests that provide results within 10-minutes, with the ability to detect IgG antibodies at a 97.3% accuracy and IgM antibodies at a 99.1% accuracy. With established relationships with over 5,000 healthcare provider clients nationwide, ranging from private medical practices to major hospitals, we believe iRemedy is an exemplary commercial partner for Adial and we look forward to continuing to build our sales and distribution relationship.\"\"We have experienced first-hand the value of COVID-19 antibody tests, which are being used to enhance patient safety and maximize subject retention during our ongoing landmark ONWARD™ pivotal Phase 3 clinical trial of AD04, for the treatment of Alcohol Use Disorder,\" stated William Stilley, Chief Executive Officer of Adial Pharmaceuticals. \"Given iRemedy's healthcare c...